Table 2.
Genes with two-fold or greater (p < 0.05) differential expression after pioglitazone treatment.
| Accession # | Δ1 (pioglitazone) | Δ2 (C57BL/6J) | Gene name |
| NM_008493.3 | 0.28 | 0.17 | leptin (Lep) |
| NM_009640.2 | 0.35 | 0.65 | angiopoietin (Agpt) |
| NM_177839.2 | 0.44 | 0.61 | tenascin N (Tnn) |
| CF906297.1 | 0.46 | 0.37 | formyltetrahydrofolate synthetase domain 1 |
| AK083494.1 | 0.46 | 0.72 | ubiquitin specific protease 29 |
| NM_008260.1 | 0.47 | 0.54 | forkhead box A3 (Foxa3) |
| CK329907.1 | 0.49 | 0.45 | aconitase 2, mitochondrial |
| AK005115.1 | 0.50 | 0.85 | zinc-finger RNA-binding domain containing 1 |
| NM_025914.1 | 0.50 | 0.65 | actin-related protein 6 homolog, ARP6 |
| NM_020581.1 | 0.50 | 0.88 | angiopoietin-like 4 (Angptl4) |
| NM_008962.2 | 2.00 | 2.54 | prostaglandin D receptor (Ptgdr) |
| NM_178779.2 | 2.00 | 2.40 | ring finger protein 152 |
| BC025027.1 | 2.00 | 1.59 | similar to phospholipase C, epsilon |
| NM_021462.2 | 2.02 | 1.92 | MAP kinase-interacting ser/thr kinase 2 |
| NM_134249.3 | 2.04 | 2.05 | T-cell immunoglobulin/mucin domain 2 (Timd2) |
| NM_011904.1 | 2.05 | 1.84 | tolloid-like 2 (Tll2) |
| AK053616.1 | 2.07 | 1.77 | prostaglandin E receptor 1 |
| NM_009188.1 | 2.08 | 2.52 | transcriptional regulator, SIN3B (Sin3b) |
| BY482739.1 | 2.08 | 1.54 | membrane associated guanylate kinase interacting-1 |
| AI604236.1 | 2.32 | 1.50 | E74-like factor 1 |
| NM_021447.1 | 2.50 | 2.05 | ring finger protein 30 (Rnf30) |
| NM_020509.2 | 2.62 | 1.04 | resistin-like alpha (RELMα) |
| NM_008830.1 | 2.82 | 2.18 | ATP-binding cassette, subfamily B, member 4 |
| NM_148937.1 | 3.33 | 1.81 | phospholipase Cδ 4 |
| AF223416.1 | 3.55 | 1.85 | cardiac triadin isoform 2 mRNA |
| NM_198864.2 | 3.58 | 1.91 | SLIT and NTRK-like family, member 3 (Slitrk3) |
| BB393194.2 | 5.22 | 0.84 | dipeptidylpeptidase 10 |
Vehicle-treated LY mice (controls) were assigned a level of expression of 1.0 for each gene Relative expression of pioglitazone-treated LY mice (Δ1) and untreated BL non-mutant mice (Δ2) compared with control mice is expressed as the fold-difference of the mean level of expression of four (vehicle- and pioglitazone-treated) or two (untreated C57BL/6J) animals per group.